Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Clinical trial NCT02337829 · COMPLETED

Trial details

NCT number: NCT02337829
Sponsor: Acerta Pharma BV
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2015-01-12
Primary completion: 2020-06-26
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.